Combining Antidepressants with Beta ‐Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction
ConclusionsResults of this analysis suggest that initiation of certain antidepressants was associated with an increased risk for serious medical sequelae among patients concurrently receiving beta ‐blockers. Greater risk was observed with antidepressants, which potently inhibit the CYP2D6 enzyme, implying that increased morbidity may be mediated by a metabolic drug interaction.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Jaekyu Shin,
Nancy K. Hills,
Patrick R. Finley Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
More News: African Health | Bupropion | Coreg | Cymbalta | Drugs & Pharmacology | Emergency Medicine | Fluoxetine | Inderal | Liver | Medicaid | Paroxetine | Paxil | Prozac | Toprol | Urology & Nephrology | USA Health | Wellbutrin